Volume 4 Issue 2
Dec.  2020
Turn off MathJax
Article Contents
Yanhong Zhang, Shangen Zheng, Qiang Zhou, Yu Zhang, Yao Zheng, Shun Wang, Lei Liu. Clinical features and hematological findings of COVID-19 patients with blood transfusion[J]. Blood&Genomics, 2020, 4(2): 129-135. doi: 10.46701/BG.2020022020125
Citation: Yanhong Zhang, Shangen Zheng, Qiang Zhou, Yu Zhang, Yao Zheng, Shun Wang, Lei Liu. Clinical features and hematological findings of COVID-19 patients with blood transfusion[J]. Blood&Genomics, 2020, 4(2): 129-135. doi: 10.46701/BG.2020022020125

Clinical features and hematological findings of COVID-19 patients with blood transfusion

doi: 10.46701/BG.2020022020125
More Information
  • Corresponding author: Shun Wang, Department of Transfusion, Wuhan First Hospital, 215 Zhongshan Rd, Wuhan, Hubei 430022, China. E-mail: wang_shun6688@sina.com; Lei Liu, Department of Transfusion Medicine, General Hospital of Central Theater Command of PLA, 627 Wuluolu Rd, Wuhan, Hubei 430070, China. E-mail: liulei890207@163.com
  • Received Date: 2020-10-10
  • Accepted Date: 2020-12-02
  • Rev Recd Date: 2020-11-07
  • Available Online: 2021-07-01
  • Publish Date: 2020-12-30
  • This paper aims to illustrate the clinical characteristics, hematological findings, and blood transfusion information of Coronavirus disease 2019 (COVID-19) patients. Twenty-three COVID-19 patients were treated and trans-fused with blood products in Wuhan First Hospital from February 12 to March 20, 2020. The patients were divided into a survivor group and a non-survivor group, respectively, according to whether the patient had been discharged or died. The results demonstrated at the time of initial blood transfusion, that the non-survivor group possessed a lower platelet (PLT) than that of the survivor group (P < 0.001), and PLT were below the normal range in 6 (85.7%) non-survivor group and in 2 (12.5%) survivor group (P < 0.01). Over half of these patients had abnormalities in fibrinogen (FIB), activated partial thromboplastin time (APTT), prothrombin time (PT), and international nor-malized ratio (INR), but no significant difference was found between the non-survivor group and survivor group. The non-survivor group had a dramatically higher D-Dimers and disseminated intravascular coagulation (DIC) scores than those of the survivor group (P < 0.01). Six (85.7%) non-survivors but none of the survivors had a DIC score greater than 6 (P < 0.001). Fifteen (93.8%) survivors and 2 (28.6%) non-survivors were transfused with RBC (P < 0.01). The non-survivors (5/7) possessed a higher proportion for using AP than the survivors (2/16). The study suggests that COVID-19 patients who undergo blood transfusion usually possess coagulation dysfunction, and DIC may be closely related to deteriorating clinical outcomes.


  • Conflict of interests: The authors declare that no conflict of interest exists.
  • loading
  • [1]
    Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(1223): 497-506. http://www.sciencedirect.com/science/article/pii/S0140673620301835
    Zhu N, Zhang DY, Wang WL, et al. A novel coronavirus from patients with pneumonia in China, 2019[J]. N Engl J Med, 2020, 382(8): 727-733. doi: 10.1056/NEJMoa2001017
    Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med, 2020, 382(18): 1708-1720. doi: 10.1056/NEJMoa2002032
    Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia[J]. J Thromb Haemost, 2020, 18(4): 844-847. doi: 10.1111/jth.14768
    Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection[J]. Clin Chem Lab Med, 2020, 58(7): 1116-1120. doi: 10.1515/cclm-2020-0188
    Fei Y, Tang N, Liu H, et al. Coagulation dysfunction: a hallmark in COVID-19[J]. Arch Pathol Lab Med, 2020, 144(10): 1223-1229. doi: 10.5858/arpa.2020-0324-SA
    World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance[EB/OL]. (2020-01-28)[2020-01-31]. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected.
    General Office of National Health Committee. Office of state administration of traditional Chinese medicine[EB/OL]. (2020-02-09)[2020-12-02]. http://bgs.satcm.gov.cn/zhengcewenjian/2020-02-09/12930.html.
    Hu Y, Mei H. Consensus of Chinese experts on diagnosis of disseminated intravascular coagulation (version 2017) [J]. Zhonghua xue ye xue za zhi (in Chinese), 2017, 38(5): 361-363. http://www.researchgate.net/publication/329267036_Consensus_of_Chinese_experts_on_diagnosis_of_disseminated_intravascular_coagulation_version_2017
    Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China[J]. JAMA Intern Med, 2020, 180(7): 934-943. doi: 10.1001/jamainternmed.2020.0994
    Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis[J]. Thromb Haemost, 2020, 120(5): 876-878. doi: 10.1055/s-0040-1709650
    Fan BE, Chong V, Chan S, et al. Hematologic parameters in patients with COVID-19 infection[J]. Am J Hematol, 2020, 95(6): E131-E134. http://www.researchgate.net/publication/346348300_Hematologic_parameters_in_coronavirus_infection_COVID-19_and_their_clinical_implications
    Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy[J]. J Thromb Haemost, 2020, 18(5): 1094-1099. doi: 10.1111/jth.14817
    Page MJ, Pretorius E. A champion of host defense: a generic large-scale cause for platelet dysfunction and depletion in infection[J]. Semin Thromb Hemost, 2020, 46(3): 302-319. doi: 10.1055/s-0040-1708827
    Thachil J. What do monitoring platelet counts in COVID-19 teach us? [J]. J Thromb Haemost, 2020, 180(7): 934-943. doi: 10.1111/jth.14879
    Harenberg J, Favaloro E. COVID-19: progression of disease and intravascular coagulation-present status and future perspectives[J]. Clin Chem Lab Med, 2020, 58(7): 1029-1036. doi: 10.1515/cclm-2020-0502
  • 加载中


    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(3)

    Article Metrics

    Article views (17) PDF downloads(1) Cited by()
    Proportional views


    DownLoad:  Full-Size Img  PowerPoint